William Oh, MD
img_William Oh
CLINICAL PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, New York University School of Medicine

Residency, General Practice, Brigham & Womens Hospital

Fellowship, Medical Oncology, Dana-Farber Cancer Institute

Certifications

American Board of Internal Medicine

Election to Alpha Omega Alpha, 1992

Prize in Internal Medicine, NYU School of Medicine, 1992

ASCO/AACR Methods in Clinical Cancer Research Workshop, 1997

Dunkin Donuts Rising Stars Award, 2002-2003

Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention, 2003

Award Recipient, Loan Repayment Program for Clinical Research, NIH, 2004

Marquis Who’s Who in America, 2004-Present

Brigham/Harvard Business School Physician Leadership Program, 2007-2008

Patients Choice Award (vitals.com), 2008-2009

Excellence in Grand Rounds, Department of Medicine, MSSM, 2010

Election to the American Society of Clinical Investigation (ASCI), 2011

Fellow, American College of Physicians (FACP), 2013

Physician Honoree, Mount Sinai Prostate Cancer Center of Excellence, 2020

America’s Top Doctors for Cancer, 2010-2022

Top Doctors: New York Metro Area, 2010-2022

America’s Top Doctors, 2010-2022

New York Super Doctors, 2011-2022

New York Magazine “Best Doctors”, 2010-2022

Best Doctors in America, 2003-2022

Boston Magazine “Top Doctors”, 2005-2009

Newsweek, 2015

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC
William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer
William Oh, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Oh during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Cytogen Corporation
  • NTx
  • Archetype Therapeutics
  • Sumitomo Pharmaceuticals, Osaka,Japan

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Sema4

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.